



## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3376	((544/328) or (514/256)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/07/31 22:45



chain nodes :

10 11 13

ring nodes :

1 2 3 4 5 6 7 8 9 14 15 16 17 18 19

chain bonds :

7-13 9-10 10-11 13-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

4-7 7-8 8-9 9-10 10-11

exact bonds :

5-9 7-13 13-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 1 : 14 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS13:CLASS14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

Generic attributes :

10:





Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :  
Node 10: Limited  
C,C4  
N,N2  
O,O0  
S,S0



chain nodes :

10 11 13 23 24 25 26 27 31 32 36 37 38

ring nodes :

1 2 3 4 5 6 7 8 9 14 15 16 17 18 19

chain bonds :

7-13 9-10 10-11 13-15 23-24 25-26 26-27 31-32 36-37 37-38

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

4-7 7-8 8-9 9-10 10-11 23-24 25-26 26-27 31-32

exact bonds :

5-9 7-13 13-15 36-37 37-38

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 1 : 14 :

G1:O,N

G2:SO2,Cy,[\*1],[\*2],[\*3],[\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS13:CLASS14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 23:CLASS24:CLASS25:CLASS26:CLASS27:CLASS31:CLASS32:Atom 36:CLASS 37:CLASS38:CLASS

Generic attributes :

10:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 10: Limited

C,C4

N,N2



O,O0

S,S0

10/521,540

=>

Uploading C:\Program Files\Stnexp\Queries\10521540.str



chain nodes :  
10 11 13  
ring nodes :  
1 2 3 4 5 6 7 8 9 14 15 16 17 18 19  
chain bonds :  
7-13 9-10 10-11 13-15  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 14-15 14-19 15-16 16-17 17-18  
18-19  
exact/norm bonds :  
4-7 7-8 8-9 9-10 10-11  
exact bonds :  
5-9 7-13 13-15  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19  
isolated ring systems :  
containing 1 : 14 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

Generic attributes :

10:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 10: Limited

C,C4

N,N2

O,O0


S,S0

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 13:25:50 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 232 TO ITERATE

100.0% PROCESSED 232 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3727 TO 5553

PROJECTED ANSWERS: 22 TO 418

L2 11 SEA SSS SAM L1

=> => s 11 sss ful

FULL SEARCH INITIATED 13:30:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4152 TO ITERATE

100.0% PROCESSED 4152 ITERATIONS

223 ANSWERS

SEARCH TIME: 00.00.01

L3 223 SEA SSS FUL L1

=> => s 13

10/521,540

L4 92 L3

=> =>

Uploading C:\Program Files\Stnexp\Queries\10521540 (sub).str



chain nodes :  
10 11 13 23 24 25 26 27 31 32 36 37 38  
ring nodes :  
1 2 3 4 5 6 7 8 9 14 15 16 17 18 19  
chain bonds :  
7-13 9-10 10-11 13-15 23-24 25-26 26-27 31-32 36-37 37-38  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 14-15 14-19 15-16 16-17 17-18  
18-19  
exact/norm bonds :  
4-7 7-8 8-9 9-10 10-11 23-24 25-26 26-27 31-32  
exact bonds :  
5-9 7-13 13-15 36-37 37-38  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19  
isolated ring systems :  
containing 1 : 14 :

G1:O,N

G2:SO2,Cy, [\*1], [\*2], [\*3], [\*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 23:CLASS  
24:CLASS 25:CLASS 26:CLASS 27:CLASS 31:CLASS 32:Atom 36:CLASS 37:CLASS  
38:CLASS



## Generic attributes :

10:

Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : 2 or more  
 Type of Ring System : Monocyclic

## Element Count :

Node 10: Limited

C,C4

N,N2

O,O0

S,S0

L5 STRUCTURE UPLOADED

=&gt; d 15

L5 HAS NO ANSWERS

L5 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=&gt; s 15 sss sub=13 sam

SAMPLE SUBSET SEARCH INITIATED 13:37:11 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.02

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE \*\*COMPLETE\*\*

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

22 TO 418

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

8 TO 329

L6 8 SEA SUB=L3 SSS SAM L5

=&gt; =&gt; s 15 sss sub=13 ful

FULL SUBSET SEARCH INITIATED 13:38:11 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 223 TO ITERATE

100.0% PROCESSED 223 ITERATIONS

135 ANSWERS

SEARCH TIME: 00.00.01

L7 135 SEA SUB=L3 SSS FUL L5

=&gt; s 13 not 17

L8 88 L3 NOT L7

=&gt; =&gt; s 18

L9 14 L8

=&gt; d 19 1-14 bib,ab,hitstr

L9 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:451231 CAPLUS  
 DN 142:476243  
 TI Soluble guanylate cyclase stimulator combination with a lipid-lowering substance, and therapeutic use  
 IN Bischoff, Hilmar; Stasch, Johannes-Peter; Weigand, Stefan  
 PA Bayer Healthcare A.-G., Germany  
 SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005046725	A1	20050526	WO 2004-EP12049	20041026
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10351903	A1	20050609	DE 2003-10351903	20031106
	CA 2544621	A1	20050526	CA 2004-2544621	20041026
	EP 1682182	A1	20060726	EP 2004-790834	20041026
	R: DE, ES, FR, GB, IT				
	JP 2007509995	T	20070419	JP 2006-538689	20041026
PRAI	DE 2003-10351903	A	20031106		
	WO 2004-EP12049	W	20041026		

OS MARPAT 142:476243

AB The invention relates to a combination preparation containing at least one active

substance (A) and at least one active substance (B), as pharmaceutically active ingredients. Active component (A) is a direct stimulator of the soluble guanylate cyclase of formula I [R1 = NR3C(O)OR4; R2 = H, NH2; R3 = H, C1-4 alkyl; R4 = C1-6 alkyl] and active component (B) is a lipid-lowering substance. The combination of the invention may be used in the treatment of e.g. cardiovascular diseases. Compound preparation is included.

IT 428854-24-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(soluble guanylate cyclase stimulator combination with lipid-lowering substance)

RN 428854-24-4 CAPLUS

CN 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)

10/521,540



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:80687 CAPLUS  
 DN 140:146158  
 TI Preparation of pyrazolopyridinylpyrimidinamines as CNS agents.  
 IN Feurer, Achim; Luithle, Joachim; Wirtz, Stephan-nicholas; Koenig, Gerhard;  
Stasch, Johannes-peter; Stahl, Elke; Schreiber, Rudy; Wunder, Frank; Lang,  
 Dieter  
 PA Bayer Healthcare Ag, Germany  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009590	A1	20040129	WO 2003-EP7236	20030707
	WO 2004009590	A8	20050512		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10232571	A1	20040205	DE 2002-10232571	20020718
	CA 2492726	A1	20040129	CA 2003-2492726	20030707
	AU 2003281477	A1	20040209	AU 2003-281477	20030707
	EP 1525203	A1	20050427	EP 2003-740426	20030707
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005537274	T	20051208	JP 2004-522410	20030707
	US 2006014951	A1	20060119	US 2005-521540	20050711
PRAI	DE 2002-10232571	A	20020718		
	WO 2003-EP7236	W	20030707		

OS MARPAT 140:146158  
 AB Title compds. [I; R1 = H, F; R2 = (alkoxy-, cycloalkyl-, aryl-, heteroaryl-substituted) alkyl], were prepared for treatment of perception, concentration, learning, and memory disorders (no data). Thus, 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide (preparation given) was refluxed 32 h with Me 3-oxobutanoate in PhMe to give 72% 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-4-pyrimidinol. The latter was heated with POCl<sub>3</sub> at 100° to give 77% 3-(4-chloro-6-methyl-2-pyrimidinyl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine. Treatment of this with 3-ethoxypropylamine in Me<sub>2</sub>SO at 60° for 48 h gave N-[3-(ethoxy)propyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-4-pyrimidinamine.

IT 651347-48-7P 651347-50-1P 651347-52-3P  
 651347-54-5P 651347-56-7P 651347-58-9P  
 651347-60-3P 651347-62-5P 651347-64-7P  
 651347-66-9P 651347-68-1P 651347-70-5P  
 651347-72-7P 651347-74-9P 651347-76-1P  
 651347-78-3P 651347-80-7P 651347-82-9P  
 651347-84-1P 651347-86-3P 651347-88-5P  
 651347-90-9P 651347-92-1P 651347-94-3P  
 651347-96-5P 651347-99-8P 651348-01-5P  
 651348-03-7P 651348-05-9P 651348-07-1P


651348-09-3P 651348-11-7P 651348-13-9P  
 651348-14-0P 651348-15-1P 651348-16-2P  
 651348-17-3P 651348-19-5P 651348-20-8P  
 651348-22-0P 651348-24-2P 651348-26-4P  
 651348-28-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrazolopyridinylpyrimidinamines as CNS agents)


RN 651347-48-7 CAPLUS

CN 4-Pyrimidinamine, N-(3-ethoxypropyl)-2-[1-[(2-fluorophenyl)methyl]-1H-  
 pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-50-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-  
 3-yl]-6-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 651347-52-3 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-  
 3-yl]-6-methyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 651347-54-5 CAPLUS

CN 4-Pyrimidinamine, N-(cyclopropylmethyl)-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-56-7 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-N-[(2-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-58-9 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-N-[(4-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-60-3 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 651347-62-5 CAPLUS


CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 651347-64-7 CAPLUS


CN 4-Pyrimidinamine, N-[2-(2-fluorophenyl)ethyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)






RN 651347-66-9 CAPLUS

CN 4-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-68-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-N-(3-methoxybutyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-70-5 CAPLUS

CN 4-Pyrimidinamine, N-(3-ethoxybutyl)-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-72-7 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 651347-74-9 CAPLUS

CN 4-Pyrimidinamine, N-[(4-fluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-76-1 CAPLUS

CN 4-Pyrimidinamine, N-[(3-fluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-78-3 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 651347-80-7 CAPLUS

CN 4-Pyrimidinamine, N-[(2,4-difluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-82-9 CAPLUS

CN 4-Pyrimidinamine, N-[(2-fluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-84-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 651347-86-3 CAPLUS

CN 4-Pyrimidinamine, N-[(3,4-difluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-88-5 CAPLUS

CN 4-Pyrimidinamine, N-[(2-chloro-6-fluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-90-9 CAPLUS

CN 4-Pyrimidinamine, N-[(2,6-difluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651347-92-1 CAPLUS

CN 4-Pyrimidinamine, N-[(3,5-dimethoxyphenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 651347-94-3 CAPLUS


CN 4-Pyrimidinamine, N-[(3,5-difluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 651347-96-5 CAPLUS


CN 4-Pyrimidinamine, N-(3-ethoxypropyl)-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)






RN 651347-99-8 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 651348-01-5 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 651348-03-7 CAPLUS

CN 4-Pyrimidinamine, N-(cyclopropylmethyl)-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-05-9 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-N-[(2-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-07-1 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-N-[(4-methoxyphenyl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-09-3 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 651348-11-7 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-N-[2-(2-fluorophenyl)ethyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-13-9 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-N-[2-(3-fluorophenyl)ethyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-14-0 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-N-(3-methoxybutyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-15-1 CAPLUS

CN 4-Pyrimidinamine, N-(3-ethoxybutyl)-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-16-2 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 651348-17-3 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-N-[(4-fluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-19-5 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-N-[(3-fluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 651348-20-8 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-N-[(2-fluorophenyl)methyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 651348-22-0 CAPLUS


CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 651348-24-2 CAPLUS


CN 4-Pyrimidinamine, N-[(2,6-difluorophenyl)methyl]-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)






RN 651348-26-4 CAPLUS

CN 4-Pyrimidinamine, N-[(3,5-dimethoxyphenyl)methyl]-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 651348-28-6 CAPLUS

CN 4-Pyrimidinamine, N-[(3,5-difluorophenyl)methyl]-5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:913163 CAPLUS  
 DN 139:395943

TI Preparation of [(pyrazolopyridinyl)pyrimidinyl]carbamates stimulating soluble guanylate cyclase for treating cardiovascular diseases and/or sexual dysfunction

IN Alonso-alija, Cristina; Bischoff, Erwin; Muentner, Klaus; Stasch, Johannes-Peter; Stahl, Elke; Weigand, Stefan; Feurer, Achim

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095451	A1	20031120	WO 2003-EP4304	20030425
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10220570	A1	20031120	DE 2002-10220570	20020508
	AU 2003233061	A1	20031111	AU 2003-233061	20030425
	CA 2485143	A1	20031120	CA 2003-2485143	20030425
	EP 1506193	A1	20050216	EP 2003-727359	20030425
	EP 1506193	B1	20060621		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009855	A	20050301	BR 2003-9855	20030425
	CN 1665811	A	20050907	CN 2003-816160	20030425
	JP 2005531553	T	20051020	JP 2004-503467	20030425
	AT 330957	T	20060715	AT 2003-727359	20030425
	NZ 536417	A	20060831	NZ 2003-536417	20030425
	PT 1506193	T	20061031	PT 2003-727359	20030425
	ZA 2004008925	A	20051104	ZA 2004-8925	20041104
	MX 2004PA11003	A	20050214	MX 2004-PA11003	20041105
	NO 2004005277	A	20041201	NO 2004-5277	20041201
	US 2006052397	A1	20060309	US 2005-513869	20050715
	US 7173037	B2	20070206		
PRAI	DE 2002-10220570	A	20020508		
	WO 2003-EP4304	W	20030425		

OS MARPAT 139:395943

AB Title compds. [I; R1 = NR3C(O)OR4; R2 = H, amino; R3 = H, C1-4 alkyl; R4 = C1-6 alkyl], were prepared. Thus, 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4,5,6-pyrimidinetriamine trihydrochloride (preparation given) in pyridine was stirred with ClCO2Me for 2 h at 0° followed by stirring for 12 h at room temperature to give 92% Me 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinylcarbamate. Data for biol. activity of I [R1 = N(Me)CO2Me; R2 = H] and I [R1 = N(Me)CO2Me; R2 = NH2] were given.

IT 428854-24-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of [(pyrazolopyridinyl)pyrimidinyl]carbamates stimulating soluble

10/521,540

guanylate cyclase for treating cardiovascular diseases and/or sexual dysfunction)

RN 428854-24-4 CAPLUS


CN 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:109219 CAPLUS  
 DN 139:36499  
 TI Cyclopropyl building blocks in organic synthesis. 84. A new and productive route to 1-heteroaryl cyclopropanols  
 AU Belov, Vladimir N.; Savchenko, Andrei I.; Sokolov, Viktor V.; Straub, Alexander; de Meijere, Armin  
 CS Institut für Organische Chemie, Georg-August-Universität Göttingen, Göttingen, 37077, Germany  
 SO European Journal of Organic Chemistry (2003), (3), 551-561  
 CODEN: EJOCFK; ISSN: 1434-193X  
 PB Wiley-VCH Verlag GmbH & Co. KGaA  
 DT Journal  
 LA English  
 OS CASREACT 139:36499  
 AB Methoxy[(alkoxy)cyclopropyl]propenenitrile derivs. were designed and prepared from Et cyclopropylidenacetate as a valuable precursor to various 1-heteroaryl cyclopropanols. The key intermediates in this study included 3-methoxy-2-[1-[(4-methoxyphenyl)methoxy]cyclopropyl]-2-propenenitrile and 3-methoxy-2-[1-[(2-propenyl)oxy]cyclopropyl]-2-propenenitrile (I). Condensation of I with amidines, guanidine, hydrazine, and Me thioglycolate and subsequent removal of the allyl protecting group yields 1-heteroaryl cyclopropanols such as 1-[4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]cyclopropanol (BAY 41-2272 metabolite II). II is a known very potent NO-independent stimulator of soluble guanylate cyclase. Direct cleavage of the allyl ether protecting group by palladium-catalyzed substitution with lithium p-toluenesulfinate in AcOH or treatment with cyclohexylmagnesium bromide/Ti(OiPr)<sub>4</sub> gives highly functionalized, sterically congested 1-heteroaryl cyclopropanols with intact amino and ester groups.  
 IT 540134-20-1P 540134-23-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of [(amino)pyrimidinyl]cyclopropanol derivs. and analogs from methoxy[(alkoxy)cyclopropyl]propenenitrile derivs. as key intermediates)  
 RN 540134-20-1 CAPLUS  
 CN 1-Propanone, 1-[4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 540134-23-4 CAPLUS  
 CN 1-Propanone, 1-[4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-

10/521,540

b[pyridin-3-yl]-5-pyrimidinyl]-3-ethoxy- (9CI) (CA INDEX NAME)



RE.CNT 53


THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:865563 CAPLUS  
 DN 137:353060  
 TI Preparation of pyrimidinylsulfonate-substituted pyrazolopyridines as inhibitors of cGMP degradation  
 IN Stasch, Johannes-Peter; Feurer, Achim; Weigand, Stefan; Stahl, Elke; Flubacher, Dietmar; Alonso-Alija, Cristina; Wunder, Frank; Lang, Dieter; Dembowski, Klaus; Straub, Alexander; Perzborn, Elisabeth  
 PA Bayer AG, Germany  
 SO Ger. Offen., 20 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

*Common Inv.*


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10122894	A1	20021114	DE 2001-10122894	20010511
	CA 2446812	A1	20021121	CA 2002-2446812	20020430
	WO 2002092596	A1	20021121	WO 2002-EP4733	20020430
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002316886	A1	20021125	AU 2002-316886	20020430
	EP 1390365	A1	20040225	EP 2002-745274	20020430
	EP 1390365	B1	20050202		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529185	T	20040924	JP 2002-589480	20020430
	ES 2236534	T3	20050716	ES 2002-2745274	20020430
	US 2004171832	A1	20040902	US 2004-477446	20040422
	US 6919345	B2	20050719		
	US 2005245553	A1	20051103	US 2005-175740	20050705
PRAI	DE 2001-10122894	A	20010511		
	WO 2002-EP4733	W	20020430		
	US 2004-477446	A1	20040422		
OS	MARPAT 137:353060				
AB	Title compds. [I; R1 = OSO2R3; R3 = (substituted) C1-6 alkyl, C3-8 cycloalkyl, Ph; R2 = H, (substituted) alkylcarbonyl], were prepared Thus, 4-amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinol (preparation given) in pyridine was treated with chloromethanesulfonyl chloride followed by stirring over night at 60° to give 77.3% 4-amino-2-[1-(fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl chloromethanesulfonate. The latter showed the vessel relaxation effect with IC50 = 700 nM.				
IT	474800-14-1P 474800-15-2P 474800-16-3P 474800-17-4P 474800-18-5P 474800-19-6P 474800-20-9P 474800-21-0P 474800-22-1P 474800-23-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidinylsulfonate-substituted pyrazolopyridines as inhibitors of cGMP degradation)				
RN	474800-14-1 CAPLUS				

CN Methanesulfonic acid, chloro-, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 474800-15-2 CAPLUS


CN 5-Pyrimidinol, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



RN 474800-16-3 CAPLUS


CN Ethanesulfonic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)






RN 474800-17-4 CAPLUS

CN Cyclopropanesulfonic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)




RN 474800-18-5 CAPLUS

CN 2-Propanesulfonic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)




RN 474800-19-6 CAPLUS

CN 1-Pentanesulfonic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)




RN 474800-20-9 CAPLUS

CN 1-Butanesulfonic acid, 4,4,4-trifluoro-, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)




RN 474800-21-0 CAPLUS

CN 1-Butanesulfonic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)




RN 474800-22-1 CAPLUS

CN 1-Propanesulfonic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 474800-23-2 CAPLUS

CN 5-Pyrimidinol, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, benzenesulfonate (ester) (9CI) (CA INDEX NAME)




IT 344773-45-1P 426813-76-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrimidinylsulfonate-substituted pyrazolopyridines as inhibitors of cGMP degradation)


RN 344773-45-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 426813-76-5 CAPLUS


CN 5-Pyrimidinol, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:512251 CAPLUS  
 DN 139:190571  
 TI Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. [Erratum to document cited in CA137:226160]  
 AU Straub, Alexander; Benet-Buchholz, Jordi; Frode, Rita; Kern, Armin; Kohlsdorfer, Christian; Schmitt, Peter; Schwarz, Thomas; Siefert, Hans-Martin; Stasch, Johannes-Peter  
 CS Institute of Medicinal Chemistry, Bayer AG, Pharma Research Centre, Wuppertal, D-42096, Germany  
 SO Bioorganic & Medicinal Chemistry (2002), 10(9), 3075  
 CODEN: BMECEP; ISSN: 0968-0896  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB On page 1711 and in the graphical abstract the second author's name should read Jordi Benet-Buchholz instead of Jordi Benet-Buckholz.  
 IT 304874-07-5P 370879-47-3P 428854-24-4P  
 457914-32-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase (Erratum))  
 RN 304874-07-5 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 370879-47-3 CAPLUS  
 CN 4,5,6-Pyrimidinetriamine, N5-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI)  
 (CA INDEX NAME)




RN 428854-24-4 CAPLUS

CN 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 457914-32-8 CAPLUS

CN     Ethanol, 2-[[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]amino]- (9CI)     (CA INDEX NAME)





L9 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:391284 CAPLUS  
 DN 136:401773  
 TI Preparation of pyrimidinylsulfonamide-substituted pyrazolopyridines as inhibitors of cGMP degradation  
 IN Stasch, Johannes-Peter; Feurer, Achim; Weigand, Stefan; Stahl, Elke; Flubacher, Dietmar; Alonso-Alija, Cristina; Wunder, Frank; Lang, Dieter; Dembowski, Klaus; Straub, Alexander; Perzborn, Elisabeth  
 PA Bayer AG, Germany  
 SO Ger. Offen., 22 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10057754	A1	20020523	DE 2000-10057754	20001122
	CA 2429313	A1	20020530	CA 2001-2429313	20011112
	WO 2002042302	A1	20020530	WO 2001-EP13064	20011112
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002027919	A5	20020603	AU 2002-27919	20011112
	EP 1339714	A1	20030903	EP 2001-989460	20011112
	EP 1339714	B1	20061018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517828	T	20040617	JP 2002-544436	20011112
	US 2004067937	A1	20040408	US 2003-432572	20031023
	US 7115599	B2	20061003		
PRAI	DE 2000-10057754	A	20001122		
	WO 2001-EP13064	W	20011112		

OS MARPAT 136:401773

AB Title compds. [I; R1 = H, Cl, amino; R2R3 together with the connected heteroatoms = (substituted) (N-, O-, S-interrupted) 5-7 membered heterocyclyl], were prepared Thus, 6-amino-5-(1,1-dioxido-2-isothiazolidinyl)-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyrimidinol (preparation given) was stirred with POCl<sub>2</sub>Ph for 2 h at 160° to give 60% 6-chloro-5-(1,1-dioxido-2-isothiazolidinyl)-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyrimidinamine. The latter showed the vessel relaxation effect with IC<sub>50</sub> = 290 nM.


IT 428854-17-5P 428854-19-7P 428854-21-1P  
 428854-24-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinylsulfonamide-substituted pyrazolopyridines as inhibitors of cGMP degradation)


RN 428854-17-5 CAPLUS

CN 4(1H)-Pyrimidinone, 5,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 428854-19-7 CAPLUS

CN 4,5-Pyrimidinediamine, 6-chloro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 428854-21-1 CAPLUS

CN 4,5-Pyrimidinediamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 428854-24-4 CAPLUS

CN 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:391283 CAPLUS  
 DN 136:401772  
 TI Preparation of pyrimidinyl carbamate-substituted pyrazolopyridines as  
 inhibitors of cGMP degradation  
 IN Stasch, Johannes-Peter; Feurer, Achim; Weigand, Stefan; Stahl, Elke;  
 Flubacher, Dietmar; Alonso-Alija, Cristina; Wunder, Frank; Lang, Dieter;  
 Dembowski, Klaus; Straub, Alexander; Perzborn, Elisabeth  
 PA Bayer AG, Germany  
 SO Ger. Offen., 30 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10057751	A1	20020523	DE 2000-10057751	20001122
	CA 2429309	A1	20020530	CA 2001-2429309	20011109
	WO 2002042300	A1	20020530	WO 2001-EP12966	20011109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,				
	UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002016028	A5	20020603	AU 2002-16028	20011109
	EP 1339717	A1	20030903	EP 2001-997488	20011109
	EP 1339717	B1	20050209		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517827	T	20040617	JP 2002-544434	20011109
	ES 2236360	T3	20050716	ES 2001-1997488	20011109
	US 2004082596	A1	20040429	US 2003-432571	20031023
	US 7105523	B2	20060912		
	US 2005261323	A1	20051124	US 2005-192961	20050729
PRAI	DE 2000-10057751	A	20001122		
	WO 2001-EP12966	W	20011109		
	US 2003-432571	A1	20031023		

OS CASREACT 136:401772; MARPAT 136:401772

AB Title compds. [I; R1 = H, dialkylaminocarbonyl; R2 = OCXNR3R4; X = O, S;  
 R3, R4 = H, (substituted) alkyl, alkoxyalkyl, hydroxyalkyl, alkenyl, etc.;  
 NR3R4 = (substituted) (benzannelated) 5-7 membered heterocyclyl containing an  
 addnl. heteroatom] were prepared Thus, 4-amino-2-[1-(2-fluorobenzyl)-1H-  
 pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinol (preparation given) in THF was  
 treated with NaH at room temperature, followed by stirring for 30 min at room  
 temperature and addition of 1-pyrrolidinecarbonyl chloride, to give, after  
 stirring

overnight at room temperature, 78.2% 4-amino-2-[1-(2-fluorobenzyl)-1H-  
 pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl 1-pyrrolidinecarboxylate.  
 Several I showed a vessel relaxation effect with IC50 = 0.27-0.65  $\mu$ M.


IT 426814-01-9P 426814-06-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of pyrimidinyl carbamate-substituted pyrazolopyridines as  
 inhibitors of cGMP degradation)


RN 426814-01-9 CAPLUS

CN Carbamothioic acid, diethyl-, O-[4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl] ester (9CI) (CA INDEX NAME)



RN 426814-06-4 CAPLUS

CN Carbamothioic acid, dimethyl-, O-[4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl] ester (9CI) (CA INDEX NAME)




IT 344773-45-1P 426813-76-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinyl carbamate-substituted pyrazolopyridines as inhibitors of cGMP degradation)


RN 344773-45-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 426813-76-5 CAPLUS


CN 5-Pyrimidinol, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:251260 CAPLUS  
 DN 137:226160  
 TI Metabolites of Orally Active NO-Independent Pyrazolopyridine Stimulators of Soluble Guanylate Cyclase  
 AU Straub, Alexander; Benet-Buckholz, Jordi; Frode, Rita; Kern, Armin; Kohlsdorfer, Christian; Schmitt, Peter; Schwarz, Thomas; Siefert, Hans-Martin; Stasch, Johannes-Peter  
 CS Institute of Medicinal Chemistry, Bayer AG, Pharma Research Centre, Wuppertal, D-42096, Germany  
 SO Bioorganic & Medicinal Chemistry (2002), 10(6), 1711-1717  
 CODEN: BMECEP; ISSN: 0968-0896  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB The pyrazolopyridine stimulators of soluble guanylate cyclase BAY 41-2272 and 41-8543 were oxidised in rats and dogs at their 5-pyrimidinyl-cyclopropyl and -morpholino residue. These metabolites activate the soluble guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543.  
 IT 304874-07-5P 370879-47-3P 428854-24-4P 457914-32-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase)  
 RN 304874-07-5 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 370879-47-3 CAPLUS  
 CN 4,5,6-Pyrimidinetriamine, N5-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI)  
 (CA INDEX NAME)



RN 428854-24-4 CAPLUS


CN 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 457914-32-8 CAPLUS

CN Ethanol, 2-[[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)





RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:795083 CAPLUS  
 DN 135:344495  
 TI Preparation of 3-amino-5-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-10-oxa-1,4,6,8-tetraazatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6-trien-13-ol as a stimulator of soluble guanylate cyclase.  
 IN Straub, Alexander; Alonso-Alija, Cristina; Kern, Armin; Stasch, Johannes-Peter; Dembowsky, Klaus  
 PA Bayer A.-G., Germany  
 SO Ger. Offen., 12 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10021069	A1	20011031	DE 2000-10021069	20000428
	WO 2001083490	A1	20011108	WO 2001-EP4418	20010419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI DE 2000-10021069 A 20000428

AB Title compound (I) was prepared Thus, 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide (preparation given) in PhMe was stirred with NaOMe and phenylazomalononitrile overnight at 110° followed by hydrogenation with Raney Ni catalyst to give 59.3% 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4,5,6-pyrimidinetriamine trichloride, (2) reaction of the latter in with t-BuMe<sub>2</sub>SiOCH<sub>2</sub>CHO in MeOH, and (3) stirring of the resulting 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(2-tertbutyldimethylsilyloxyethyl)imino-4,6-pyrimidinediamine with (Bu)<sub>4</sub>NF in THF for 2 h at room temperature followed by treatment with glyoxal hydrate to give 8.9% I. I at 100 µM activated soluble guanylate cyclase by a factor of 160 relative to the basal activity.


IT 370879-46-2P 370879-47-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminofluorobenzylpyrazolopyridinoxatetraazatricyclo[7.3.1.0<sup>2,7</sup>]tridecatr ienol as a stimulator of soluble guanylate cyclase)

RN 370879-46-2 CAPLUS


CN 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 370879-47-3 CAPLUS


CN 4,5,6-Pyrimidinetriamine, N5-[2-[[[1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI)  
(CA INDEX NAME)



L9 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:207062 CAPLUS  
 DN 135:40411  
 TI NO-Independent stimulators of soluble guanylate cyclase  
 AU Straub, A.; Stasch, J.-P.; Alonso-Alija, C.; Benet-Buchholz, J.; Ducke, B.; Feurer, A.; Furstner, C.  
 CS Pharma Research Centre, Institute of Medicinal Chemistry, Bayer AG, Wuppertal, D-42096, Germany  
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(6), 781-784  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 AB SARs around a novel type of guanylate cyclase stimulator which act by a mechanism different from classical NO-donors are described. Several pyrazolopyrimidinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application. The SARs around a novel type of stimulators of soluble guanylate cyclase, their relaxing effects on precontracted rabbit aortic rings (measured as IC50s) and their hypotensive properties are described.  
 IT 256499-12-4 256499-22-6 344773-21-3  
 344773-26-8 344773-27-9 344773-28-0  
 344773-30-4 344773-32-6 344773-35-9  
 344773-36-0 344773-41-7 344773-45-1  
 344773-47-3 344773-50-8 344773-53-1  
 344773-56-4 344773-57-5  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (NO-independent stimulators of soluble guanylate cyclase)  
 RN 256499-12-4 CAPLUS  
 CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 256499-22-6 CAPLUS  
 CN 4-Pyrimidinamine, 5-ethyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 344773-21-3 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 344773-26-8 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-methyl- (9CI) (CA INDEX NAME)




RN 344773-27-9 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-propyl- (9CI) (CA INDEX NAME)




RN 344773-28-0 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 344773-30-4 CAPLUS

CN 4-Pyrimidinamine, 5-butyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 344773-32-6 CAPLUS

CN 4-Pyrimidinamine, 5-(1,1-dimethylethyl)-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 344773-35-9 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pentyl- (9CI) (CA INDEX NAME)




RN 344773-36-0 CAPLUS  
 CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-hexyl- (9CI) (CA INDEX NAME)




RN 344773-41-7 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 344773-45-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 344773-47-3 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(methylthio)- (9CI) (CA INDEX NAME)




RN 344773-50-8 CAPLUS

CN Phosphonic acid, [4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 344773-53-1 CAPLUS

CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 344773-56-4 CAPLUS

CN 5-Pyrimidinemethanamine, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 344773-57-5 CAPLUS


CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2000:790500 CAPLUS  
 DN 133:350132  
 TI Preparation of cyclopropylpyrimidazinyipyridinopyrazole derivative for treatment of cardiovascular diseases.  
 IN Straub, Alexander; Feurer, Achim; Alonso-Alija, Cristina; Stahl, Elke; Stasch, Johannes-Peter; Perzborn, Elisabeth; Dembowsky, Klaus; Kern, Armin  
 PA Bayer Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 23 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066582	A1	20001109	WO 2000-EP3620	20000420
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19920352	A1	20001109	DE 1999-19920352	19990504
PRAI	DE 1999-19920352	A	19990504		
AB	The substituted pyrazole derivative (I) is claimed and well as its method of preparation and use in the treatment of cardiovascular diseases. Thus, I was prepared in a multistep process starting with Na salt of Et cyano-2-oxopropanoate and 2-fluorobenzylhydrazine.				
IT	304874-07-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and reactant for preparation of cyclopropylpyrimidazinyipyridinopyrazole for treatment of cardiovascular diseases)				
RN	304874-07-5 CAPLUS				
CN	5-Pyrimidinecarboxylic acid, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

L9 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:83168 CAPLUS

DN 132:137398

TI Preparation of (4-amino-5-ethylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine as cardiovascular drug

IN Straub, Alexander; Feurer, Achim; Fuerstner-Roby, Chantal; Alonso-Alija, Cristina; Stasch, Johannes-Peter; Perzborn, Elisabeth; Huetter, Joachim; Dembowsky, Klaus; Stahl, Elke

PA Bayer A.-G., Germany

SO Ger. Offen., 12 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19834045	A1	20000203	DE 1998-19834045	19980729
	WO 2000006567	A1	20000210	WO 1999-EP5071	19990716
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9951604	A1	20000221	AU 1999-51604	19990716
	EP 1104421	A1	20010606	EP 1999-936550	19990716
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002521481	T	20020716	JP 2000-562369	19990716
PRAI	DE 1998-19834045	A	19980729		
	WO 1999-EP5071	W	19990716		

AB The title compound (I), useful for the treatment of cardiovascular diseases, thromboembolism and ischemia, was prepared by condensation reaction of amidine II (prepared and claimed) with enamine MeCH<sub>2</sub>C(CN):CHNMe<sub>2</sub>. II was obtained by dehydration reaction of the parent amide to a nitrile, conversion of the nitrile to imino ester with MeONa in MeOH, conversion of the imino ester to amidine-HCl with NH<sub>4</sub>Cl and AcOH in MeOH and basification of the salt with Na<sub>2</sub>CO<sub>3</sub>. The use of I as cardiovascular drug and pharmaceuticals containing I in combination with organic nitrates,

NO-donors

and with compds. that inhibit degradation of cyclic guanosine monophosphate are also claimed.


IT 256499-22-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (4-amino-5-ethylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine as cardiovascular drug)

RN 256499-22-6 CAPLUS

CN 4-Pyrimidinamine, 5-ethyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2000:83167 CAPLUS  
 DN 132:137382  
 TI Preparation of benzylpyrazolopyridines and related compounds as  
 cardiovascular agents.  
 IN Straub, Alexander; Feurer, Achim; Alonso-Alija, Cristina; Stasch,  
 Johannes-Peter; Perzborn, Elisabeth; Huetter, Joachim; Dembowski, Klaus;  
 Stahl, Elke  
 PA Bayer A.-G., Germany  
 SO Ger. Offen., 36 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19834044	A1	20000203	DE 1998-19834044	19980729
	CA 2339071	A1	20000210	CA 1999-2339071	19990716
	WO 2000006569	A1	20000210	WO 1999-EP5074	19990716
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9952840	A	20000221	AU 1999-52840	19990716
	AU 751316	B2	20020815		
	BR 9912562	A	20010502	BR 1999-12562	19990716
	EP 1102768	A1	20010530	EP 1999-938273	19990716
	EP 1102768	B1	20051221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	TR 200100238	T2	20010621	TR 2001-200100238	19990716
	JP 2002521483	T	20020716	JP 2000-562371	19990716
	HU 200103815	A2	20020729	HU 2001-3815	19990716
	NZ 509599	A	20030725	NZ 1999-509599	19990716
	RU 2232161	C2	20040710	RU 2001-105938	19990716
	AT 313543	T	20060115	AT 1999-938273	19990716
	ES 2255288	T3	20060616	ES 1999-938273	19990716
	TW 509691	B	20021111	TW 1999-88112743	19990728
	NO 2001000149	A	20010326	NO 2001-149	20010109
	NO 319073	B1	20050613		
	ZA 2001000222	A	20010807	ZA 2001-222	20010109
	IN 2001MN00084	A	20050715	IN 2001-MN84	20010122
	BG 105177	A	20011130	BG 2001-105177	20010124
	MX 2001PA00991	A	20010910	MX 2001-PA991	20010126
	US 6743798	B1	20040601	US 2001-744830	20010411
	HK 1040712	A1	20050520	HK 2002-102366	20020327
	US 2004224945	A1	20041111	US 2004-856153	20040528
	IN 2004MN00603	A	20050520	IN 2004-MN603	20041027
PRAI	DE 1998-19834044	A	19980729		
	WO 1999-EP5074	W	19990716		
	IN 2001-MN84	A3	20010122		
	US 2001-744830	A3	20010411		

OS MARPAT 132:137382

AB Title compds. [I; R1 = saturated or aromatic 5-6 membered (substituted)  
 heterocyclyl, etc.; R2R3 = atoms to form a 6-membered saturated or aromatic  
 (substituted) heterocyclyl; A = 5-6 membered aromatic or saturated  
 (substituted)



heterocyclyl, Ph], were prepared Thus, 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide (preparation given), 3-dimethylamino-2-methylsulfonyl-2-propenenitrile, piperidine, and isoamyl alc. were heated 12 h at 110° to give 31.8% 3-(4-amino-5-methylsulfonylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine. Tested I increased cGMP levels by 600% to >1000%.

IT 256498-65-4P 256498-68-7P 256498-89-2P


256499-09-9P 256499-10-2P 256499-12-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzylpyrazolopyridines and related compds. as cardiovascular agents)


RN 256498-65-4 CAPLUS

CN 4,6-Pyrimidinediamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 256498-68-7 CAPLUS

CN 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-N5-(2-methoxyethyl)-N5-methyl- (9CI) (CA INDEX NAME)




RN 256498-89-2 CAPLUS

CN 4-Pyrimidinamine, N,5-diethyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 256499-09-9 CAPLUS

CN Phosphonic acid, [4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 256499-10-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-amino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 256499-12-4 CAPLUS

CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




IT 256499-22-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of benzylpyrazolopyridines and related compds. as  
cardiovascular agents)

RN 256499-22-6 CAPLUS

CN 4-Pyrimidinamine, 5-ethyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



10/521,540

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

74.25

297.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-10.92

-10.92

STN INTERNATIONAL LOGOFF AT 13:39:27 ON 31 JUL 2007